Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05462067
Other study ID # GPAS-LARALISA-2018-01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 14, 2019
Est. completion date November 20, 2020

Study information

Verified date July 2022
Source Carl Zeiss Meditec AG
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to obtain postoperative visual performance data of patients with bilateral implantation of the AT LARA IOL or the AT LARA implanted in the dominant eye and AT LISA tri implanted in the other eye. Dependence on spectacles, the occurrence of photic phenomena and patient and surgeon satisfaction with the patient's visual performance will be documented. Furthermore, the refraction data will be used to optimize the IOL constants for IOL power calculations.


Description:

An extended depth of field can enable patients to do most everyday tasks without glasses. Compared to MIOLs, side effects such as glare and halo perception are expected to be less frequent and with lower intensity. This study is designed to assess visual performance and satisfaction in patients who underwent bilateral AT LARA IOL implantation or a mixed implantation of AT LARA in the dominant eye and AT LISA tri in the non-dominant eye. All patients will be offered enrolment after successful implantation in both eyes. Therefore, the preoperative and surgical data are recorded retrospectively, the follow-up examinations will be documented prospectively. This approach is justified and does not cause bias, as the purpose of this study is to investigate the performance of the IOL after successful implantation and uncomplicated surgery. In this retrospective/prospective, non-randomized study, subjects will receive either binocular implantation of AT LARA/AT LARA toric or AT LARA/AT LARA toric in the distance dominant eye and AT LISA tri/AT LISA tri toric in the non-dominant eye. The main outcome parameter is best corrected visual acuity (CDVA). Secondary outcome parameters are: preferred near and intermediate distance, UDVA, DCIVA (Salzburg Reading desk in preferred distance), DCNVA (Salzburg Reading Desk in preferred near distance), distance corrected intermediate and near visual acuity with different contrast settings (Salzburg Reading Desk), manifest refraction, monocular and binocular defocus curve analysis, dysphotopsia simulation (Halo & Glare Simulator), subjective patient satisfaction (MacAlinden) questionnaire. Patients have different demands for intermediate and near vision as well as distances needed for daily routine. Comparing both groups indicates there is individual lens fitting for patients depending on their own needs. Subjects are to be evaluated 2-4 months and 5-8 months after implantation of either configuration.


Recruitment information / eligibility

Status Completed
Enrollment 72
Est. completion date November 20, 2020
Est. primary completion date November 20, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients bilaterally implanted with the AT LARA IOL or the AT LARA and AT LISA tri IOLs or their toric versions - Age 18 and older - Uncomplicated implantation of study IOLs - No visual acuity limiting pathologies - Clear intraocular media - Availability, willingness and sufficient cognitive awareness to comply with examination procedures - Written informed consent for participation in the study and data protection Exclusion Criteria: - Visual potential of less than 0.63 (decimal) in each eye due to ocular pathologies, e.g. retinal disorders - Postoperative CDVA >0.2 log MAR - Visual field loss which has impact on visual acuity - Use of systemic or ocular medication that might affect vision - Acute or chronic disease, illness, ocular trauma or surgery that would confound results (e.g. macular degeneration, cystoid macular edema, proliferative diabetic retinopathy, etc.) - Patients with amblyopia, strabismus, forme fruste keratoconus or keratoconus - Capsular or zonular abnormalities that have affected postoperative centration or tilt of the lens (e.g. pseudoexfoliation syndrome) - Pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils, or pupils that do not dilate at least 3.5 mm under mesopic/scotopic conditions) - Patient participates in other clinical trial (former participation is no exclusion criterion)

Study Design


Related Conditions & MeSH terms


Intervention

Device:
AT LARA IOL
EDOF IOL for treatment of cataract
AT LISA Tri IOL
Trifocal IOL for treatment of cataract

Locations

Country Name City State
Denmark Hellerup Øjenklinik Hellerup
Germany Goethe University Frankfurt
Germany Augentagesklinik Rheine Rheine
Ireland Cathedral Eye Clinic Belfast

Sponsors (1)

Lead Sponsor Collaborator
Carl Zeiss Meditec AG

Countries where clinical trial is conducted

Denmark,  Germany,  Ireland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in preoperative and postoperative binocular Corrected Distance Visual Acuity (CDVA) The uncorrected and best corrected distance visual acuity is determined with standard reading charts at a distance of 4 or 5 m; logMar visual acuity is recorded.
Near visual acuity (40 cm) and intermediate visual acuity (67 cm) are documented using suitable visual acuity charts for the respective distance or converted using conversion tables. The logMar visual acuity is recorded.
Uncorrected visual acuity will be scored for distance, intermediate and near vision:
logMAR 0.0 or better = 5
logMar 0.1 = 4
logMar 0.2 = 3
logMar 0.3 = 2
logMAR worse than 0.3 = 1 Scores for the individual distances will be added to a total score.
Pre-op, 2-4 Months, & 5-8 Months
Secondary Postoperative uncorrected monocular and binocular distance visual acuity The uncorrected and best corrected distance visual acuity is determined with standard reading charts at a distance of 4 or 5 m; logMar visual acuity is recorded.
Near visual acuity (40 cm) and intermediate visual acuity (67 cm) are documented using suitable visual acuity charts for the respective distance or converted using conversion tables. The logMar visual acuity is recorded.
Uncorrected visual acuity will be scored for distance, intermediate and near vision:
logMAR 0.0 or better = 5
logMar 0.1 = 4
logMar 0.2 = 3
logMar 0.3 = 2
logMAR worse than 0.3 = 1 Scores for the individual distances will be added to a total score.
2-4 Months, & 5-8 Months
Secondary Postoperative uncorrected and distance-corrected binocular near visual acuity The uncorrected and best corrected distance visual acuity is determined with standard reading charts at a distance of 4 or 5 m; logMar visual acuity is recorded.
Near visual acuity (40 cm) and intermediate visual acuity (67 cm) are documented using suitable visual acuity charts for the respective distance or converted using conversion tables. The logMar visual acuity is recorded.
Uncorrected visual acuity will be scored for distance, intermediate and near vision:
logMAR 0.0 or better = 5
logMar 0.1 = 4
logMar 0.2 = 3
logMar 0.3 = 2
logMAR worse than 0.3 = 1 Scores for the individual distances will be added to a total score.
2-4 Months, & 5-8 Months
Secondary Postoperative uncorrected and distance-corrected binocular intermediate visual acuity The uncorrected and best corrected distance visual acuity is determined with standard reading charts at a distance of 4 or 5 m; logMar visual acuity is recorded.
Near visual acuity (40 cm) and intermediate visual acuity (67 cm) are documented using suitable visual acuity charts for the respective distance or converted using conversion tables. The logMar visual acuity is recorded.
Uncorrected visual acuity will be scored for distance, intermediate and near vision:
logMAR 0.0 or better = 5
logMar 0.1 = 4
logMar 0.2 = 3
logMar 0.3 = 2
logMAR worse than 0.3 = 1 Scores for the individual distances will be added to a total score.
2-4 Months, & 5-8 Months
Secondary Reading speed and acuity, and preferred reading distance (Salzburg reading desk) Sites at which the Salzburg Reading Desk is available will examine reading speed and acuity at 40 cm and 66 cm at the two postoperative visits. The following parameters will be documented: words per minute (WPM), characters per minute (CPM), words missed (reading speed recalculated when missed words are selected), LogMAR reading acuity, average reading distance, average reading time. 2-4 Months, & 5-8 Months
Secondary Postoperative use of spectacles (near, intermediate, distance) The surgeon asks: "How often do you need glasses for near/intermediate/distance vision?". The answers are classified into 0%, 25%, 50%, 75% and 100% of the total time. 2-4 Months, & 5-8 Months
Secondary Photic phenomena The McAlinden Quality of Vision (QoV) questionnaire will be used to assess the size and intensity of halo and glare 2-4 Months, & 5-8 Months
Secondary Defocus curve Best-corrected distance defocus curve testing from +1.0 D to -4.0 D shall be performed. The image shall be defocused in -0.5 D increments with spherical minus lenses and a visual acuity measurement is obtained at each defocus increment. 2-4 Months, & 5-8 Months
Secondary Patient satisfaction The McAlinden Quality of Vision (QoV) questionnaire will be used to assess patient satisfaction. Patients are asked two closed answered questions, with Yes or No being the answer. 'Would you decide to have multifocal IOLs again?' and ' Would you recommend the same lens to your relatives and friends?' 2-4 Months, & 5-8 Months
Secondary Surgeon's assessment The surgeon completes a short questionnaire on the handling and performance of the lens. The ease of implantation, achievement of the target refraction, satisfaction with the patient's vision and general satisfaction are recorded. 2-4 Months, & 5-8 Months
Secondary Optimization of IOL-constants For this purpose, the corneal radii, the axial length, the measured anterior chamber depth and the implanted IOL power are recorded during biometry to determine the correct IOL power. Postoperatively, the subjective refraction achieved is documented as spherical equivalent and forwarded to Prof. Dr. Achim Langenbucher, Medical Faculty of Saarland University, Experimental Ophthalmology, for evaluation with the IOL-Con software 2-4 Months, & 5-8 Months
See also
  Status Clinical Trial Phase
Completed NCT04685538 - Chloroprocaine 3% Gel Eye Drop as Topical Anestheticsin Phacoemulsification. Phase 3
Recruiting NCT06060041 - IC-8 Apthera IOL New Enrollment Post Approval Study
Recruiting NCT05518539 - Evaluation of Quality of Vision and Visual Outcomes With Bilateral Implantation of the Clareon PanOptix Intraocular Lens
Recruiting NCT05271942 - Tilt and Tumble vs Divide and Conquer - a Unique Comparison of the Two Cataract Surgery Methods N/A
Active, not recruiting NCT04778501 - PMCF Study on Monofocal Toric IOL (PODEYE TORIC) in Asia N/A
Completed NCT05062564 - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye N/A
Completed NCT03751033 - Influence of DisCoVisc Ophthalmic Viscosurgical Device (OVD) on Intraoperative Aberrometry Readings N/A
Completed NCT02529488 - Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting Intraocular Lens (IOL) Model TFNT00 N/A
Completed NCT04539548 - A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract Phase 3
Completed NCT03740659 - Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery Phase 2
Completed NCT03494257 - Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification N/A
Completed NCT05119127 - Rotational Stability of Acrysof IQ Vivity Extended Vision Toric IOL and Refractive Visual Outcome. N/A
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03713268 - Intraoperative OCT Guidance of Intraocular Surgery II
Completed NCT03739528 - Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery Phase 3
Completed NCT02888210 - A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery Phase 3
Completed NCT03356847 - Evaluation of the Rotational Stability of the Monofocal SISA Implant Following Cataract Surgery N/A
Completed NCT04332640 - Clinical Evaluation of the Next Generation Phaco System N/A
Recruiting NCT03638726 - Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification Phase 4
Completed NCT03050697 - Evaluation of the Safety and Performance of the HARMONI® Toric Lens N/A